Universal Vision Biotechnology Co., Ltd. Stock

Equities

3218

TW0003218004

Medical Equipment, Supplies & Distribution

End-of-day quote Taipei Exchange 06:00:00 2024-05-15 pm EDT 5-day change 1st Jan Change
257 TWD +0.59% Intraday chart for Universal Vision Biotechnology Co., Ltd. +3.63% -7.22%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 4.36B 135M Sales 2025 * 5.07B 158M Capitalization 21.77B 676M
Net income 2024 * 1.15B 35.83M Net income 2025 * - EV / Sales 2024 * 4.49 x
Net cash position 2024 * 2.18B 67.58M Net cash position 2025 * 2.51B 77.95M EV / Sales 2025 * 3.8 x
P/E ratio 2024 *
18.9 x
P/E ratio 2025 *
-
Employees 401
Yield 2024 *
2.83%
Yield 2025 *
3.7%
Free-Float 52.5%
More Fundamentals * Assessed data
Dynamic Chart
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Health Care Down on Mixed Earnings Prospects - Health Care Roundup DJ
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Universal Vision Biotechnology Co., Ltd. Announces Principal Financial and Accounting Officer Changes CI
Universal Vision Biotechnology Co., Ltd. Announces Change of the Principal Financial and Accounting Officer CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Universal Vision Biotechnology Co., Ltd. Announce Audit Committee Appointment CI
More news
1 day+0.59%
1 week+3.63%
Current month+0.39%
1 month+0.39%
3 months-7.39%
6 months-11.07%
Current year-7.22%
More quotes
1 week
253.00
Extreme 253
264.50
1 month
236.00
Extreme 236
265.50
Current year
236.00
Extreme 236
307.00
1 year
236.00
Extreme 236
412.74
3 years
198.11
Extreme 198.1132
432.08
5 years
28.26
Extreme 28.257
432.08
10 years
16.26
Extreme 16.2624
432.08
More quotes
Managers TitleAgeSince
Chief Executive Officer - 10-01-31
Director of Finance/CFO - 16-03-31
President - 03-06-01
Members of the board TitleAgeSince
President - 03-06-01
Chairman - 12-06-27
Director/Board Member 64 12-06-27
More insiders
Date Price Change Volume
24-05-16 257 +0.59% 299,503
24-05-15 255.5 -0.78% 315,646
24-05-14 257.5 -2.28% 513,799
24-05-13 263.5 +1.74% 826,267
24-05-10 259 +4.44% 1,517,613

End-of-day quote Taipei Exchange, May 15, 2024

More quotes
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD is a Taiwan-based company principally engaged in the trading of ophthalmic supplies and the provision of eye treatment and related medical services. The Company provides laser vision correction equipment and services, as well as the trading of medical drugs, optical glasses and contact lenses. In addition, the Company is involved in the leasing of medical places, the planning of clinic operation, as well as the provision of medical cosmetology services. The Company operates its businesses mainly in Taiwan market.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
257 TWD
Average target price
305 TWD
Spread / Average Target
+18.68%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW